絞り込み

16645

広告

Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study.

著者 Chen Y , Li Q , Han Y , Ji H , Gu M , Bian R , Ding W , Cheng J , Mu Y
Diabetes Ther.2019 Dec 10 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)

Full Text Sources

Miscellaneous

The effect of dipeptidyl peptidase-4 (DDP-4) inhibitors versus α-glucosidase inhibitors (AGIs) on the treatment of type 2 diabetes mellitus (T2DM) in a real-world setting is unknown. The aim of this real-world study was to compare the glucose-lowering effect and tolerability of vildagliptin as add-on to metformin monotherapy (VM) and AGI as add-on to metformin monotherapy (AM) in Chinese patients with T2DM.
PMID: 31823167 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード